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Introduction: In this prospective pilot study, we evaluated the fea-
sibility and potential utility of measuring multiple exhaled gases as 
biomarkers of radiation pneumonitis (RP) in patients receiving ste-
reotactic ablative radiotherapy (SABR) for lung tumors.
Methods: Breath analysis was performed for 26 patients receiv-
ing SABR for lung tumors. Concentrations of exhaled nitric oxide 
(eNO), carbon monoxide (eCO), nitrous oxide (eN
2
O), and carbon 
dioxide (eCO
2
) were measured before and immediately after each 
fraction using real-time, infrared laser spectroscopy. RP development 
(CTCAE grade ≥2) was correlated with baseline gas concentrations, 
acute changes in gas concentrations after each SABR fraction, and 
dosimetric parameters.
Results: Exhaled breath analysis was successfully completed in 77% 
of patients. Five of 20 evaluable patients developed RP at a mean of 
5.4 months after SABR. Acute changes in eNO and eCO concentra-
tions, defined as percent changes between each pre-fraction and post-
fraction measurement, were significantly smaller in RP versus non-RP 
cases (p = 0.022 and 0.015, respectively). In an exploratory analysis, a 
combined predictor of baseline eNO greater than 24 parts per billion 
and acute decrease in eCO less than 5.5% strongly correlated with RP 
incidence (p = 0.0099). Neither eN
2
O nor eCO
2
 concentrations were 
significantly associated with RP development. Although generally 
higher in patients destined to develop RP, dosimetric parameters were 
not significantly associated with RP development.
Conclusions: The majority of SABR patients in this pilot study were 
able to complete exhaled breath analysis. Baseline concentrations 
and acute changes in concentrations of exhaled breath components 
were associated with RP development after SABR. If our findings are 
validated, exhaled breath analysis may become a useful approach for 
noninvasive identification of patients at highest risk for developing 
RP after SABR.
Key Words: Radiation pneumonitis, Stereotactic ablative radiother-
apy, Lung cancer, Nitric oxide, Carbon monoxide
(J Thorac Oncol. 2014;9: 957–964)
Stereotactic ablative radiotherapy (SABR), also called ste-reotactic body radiation therapy, delivers large doses of 
radiation with high precision in a small number of fractions 
and has rapidly gained acceptance as an important modality in 
the management of lung tumors. Although many studies have 
demonstrated high (more than 90%) rates of tumor control with 
SABR with limited toxicity, damage to normal surrounding 
tissues remains an important concern.1 Radiation pneumoni-
tis (RP), an inflammatory reaction that occurs within irradi-
ated lung tissue, is one of the most common toxicities after 
SABR to the lung. Symptoms of RP include cough, shortness 
of breath, fever, and changes in pulmonary function and in 
rare cases may be fatal.2. Incidence of RP after lung SABR has 
been reported to range from 9% to 28%.3 Mechanistically, RP 
is because of infiltration of leukocytes into lung tissue dam-
aged by irradiation and is accompanied by extensive cytokine 
induction. Ultimately, the inflammatory process progresses to 
fibrosis, which destroys the normal architecture of the lung.4
Several studies have evaluated the relationship between 
RP incidence after lung SABR and dosimetric parameters.3,5–7 
Although certain metrics, including mean lung dose (MLD) 
to the ipsilateral lung and tumor volume, have been shown 
to correlate with RP development, agreement between stud-
ies has been imperfect.3 Therefore, developing biomarkers to 
assess RP risk after SABR to the lung to supplement conven-
tional dosimetric analysis would be desirable.
Although not previously evaluated in SABR patients, 
elevations in the concentration of exhaled nitric oxide (eNO), 
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a biomarker of airway inflammation, after completion of 
conventionally fractionated radiotherapy (CFRT) have been 
observed to predict RP development.2,8–11 In a cohort of 29 
patients receiving CFRT for lung cancer, Koizumi et al.8 found 
that among five patients who showed increases in eNO greater 
than three times pretreatment levels after a multi-week treat-
ment course, three developed RP whereas no other patients in 
the study did. In a cohort of 50 patients receiving CFRT for 
lung and esophageal cancer, McCurdy et al.2 found greater 
than 1.4-fold increases in eNO at the end of CFRT com-
pared with baseline-predicted RP development. However, in 
a similar study of 65 patients receiving CFRT for lung cancer, 
Enache et al. concluded that serial eNO measurements had an 
overall low ability to predict symptomatic RP.10
Several commercial breath analyzers exist to measure 
eNO, including the Niox chemiluminescent device, the Niox-
MINO electrochemical device, and the Apieron solid-state gel 
detection device.12 However, these instruments are unable to 
measure additional exhaled gases and measurement agree-
ment has been variable.12 Alternatively, tunable infrared laser 
spectroscopy is a detection method that allows for highly 
accurate, reproducible, and real-time measurements of mul-
tiple gases, making it well suited for time-efficient, multicom-
ponent analyses.
The goal of the present pilot study was to assess the fea-
sibility of measuring baseline and acute changes in concentra-
tions of eNO, eCO, eN
2
O, and eCO
2
 in patients undergoing 
lung SABR. In addition, we wished to explore whether such 
measurements might serve as potential biomarkers of RP in 
patients treated with SABR for malignant lung tumors.
METHODS AND MATERIALS
Patients
A total of 26 adult patients with biopsy-confirmed pri-
mary or metastatic lung tumors that received SABR at the 
Stanford Cancer Center between August 2010 and September 
2011 underwent exhaled breath analysis as part of an insti-
tutional review board approved pilot study. Patients that had 
undergone previous radiotherapy were excluded. Patients 
were treated using previously published techniques for 
SABR.13 Briefly, during simulation, we constructed custom-
ized immobilization devices for each patient, and four-dimen-
sional computed tomography (4D-CT) and positron emission 
tomography (PET)-CT images were acquired in the treatment 
position. The gross tumor volume (GTV) was contoured on 
axial CT slices with PET guidance. Breathing-induced tumor 
motion was assessed using the four-dimensional CT and an 
internal target volume was constructed for either motion-
inclusive technique or respiratory gating, depending on the 
extent of tumor motion. A 0.5 cm setup margin was added to 
the internal target volume to form the final planning target vol-
ume (PTV). Treatment was delivered in one to five fractions 
using 6-MV photons on a Trilogy or TrueBeam STx (Varian 
Medical Systems, Palo Alto, CA) using daily kilovoltage (kV) 
x-ray portal imaging and cone-beam CT for anatomy-based 
matching. Treatment planning goals included covering at least 
95% of the PTV with the prescription dose. Heterogeneity 
corrections were used routinely for dose calculations. The 
analytic anisotropic algorithm was used and treatments were 
delivered by either dynamic conformal arc or volumetric mod-
ulated arc therapy (RapidArc, Varian).
Informed consent was obtained from all patients before 
enrollment. Forced expiratory volume in the first second 
(FEV1) of forceful exhalation and diffusing capacity of the 
lung for carbon monoxide measurements were made before 
enrollment of the subject. These measurements were later 
used to determine whether lung function correlated with an 
individual’s ability to complete exhaled breath measurements.
Exhaled Breath Measurements
We employed a breath analysis system designed and 
built by Aerodyne Research, Inc. (Billerica, MA) that uses 
real-time, tunable infrared laser spectroscopy to simultane-
ously measure eNO, eCO, eN
2
O, and eCO
2
 concentrations.12,14 
While seated and relaxed, patients inhaled NO-free air (less 
than or equal to five parts per billion [ppb]) for approximately 
3 seconds to near total lung capacity and then exhaled into the 
instrument for 20 seconds at a constant flow rate of 3 liters 
per minute. Using this method, the exhalation gas from both 
airways and alveolar regions is sampled. The total exhalation 
time of 20 seconds was chosen to ensure that the characteris-
tic eNO concentration plateau would be reached (see Fig. 1). 
Using a constant target flow rate of 3 liters per minute, we 
examined the same period and therefore the same approxi-
mate airway volume in all tests for all gases. This flow rate was 
selected because it is generally achievable for most patients 
and is the standard set by guidelines from the American 
Thoracic Society and European Respiratory Society for eNO 
breath analysis.15
Measurements of eNO, eCO, eN
2
O, and eCO
2
 concen-
trations were made within 5 minutes before and after each 
SABR fraction on each day of a patient’s course. Before mea-
surement, patients were asked to confirm any new symptoms, 
most recent inhaler and medication use, most recent cigarette 
use, and most recent oral intake. All exhaled gas concentra-
tion profiles were analyzed according to the recommendations 
of the American Thoracic Society and European Respiratory 
Society for the standardized measurement of NO.15 To exam-
ine the same airway volume for a patient, it was critical to con-
sistently analyze the same period of exhalation for all gases 
evaluated in this study. Thus, measurements for all gases were 
calculated as averages over a 3-second interval during which 
eNO reached its characteristic plateau.
Pre-fraction and post-fraction measurements were per-
formed in triplicate, and final pre-fraction and post-fraction 
concentrations were calculated as the mean of these measure-
ments. These pre-fraction and post-fraction concentrations 
were used to calculate an acute percent change for each day 
of the patient’s course. Acute changes calculated after single 
fractions were averaged across all fractions to produce an 
overall average acute percent change in each gas concentra-
tion for each patient.
Follow-up and Outcomes Assessment
RP incidence was assessed at patient follow-up visits at 3 
and 6 months after initiation of SABR. RP toxicity was scored 
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using the National Cancer Institute Common Terminology 
Criteria for Adverse Events, version 4.0 (CTCAE v4.0), with 
grade 2 or higher defined as symptomatic.16 Symptoms con-
sidered included new onset or significantly increased cough 
and shortness of breath and fevers. All patients scored with 
grade 2 RP in this study experienced new or worsened short-
ness of breath and cough, and no patients had fevers. CT or 
PET/CT imaging was used to confirm presence of inflamma-
tory changes in the irradiated region without imaging evi-
dence of pneumonia. All symptomatic patients were treated 
with inhaled or oral steroids with rapid improvement of symp-
toms. Incidence of symptomatic RP was evaluated for corre-
lation with baseline gas concentrations, acute changes in gas 
concentrations after SABR fractions, dosimetric parameters, 
and demographic factors.
Statistical Analyses
Comparisons of baseline gas concentrations and acute 
changes in gas concentrations after SABR, measured on a 
continuum and as dichotomized variables, were evaluated 
using the independent samples t test and Fisher’s exact test, 
respectively. Dosimetric parameters were compared using the 
independent samples t test. To determine the extent to which 
the breath analysis equipment was producing repeatable 
measurements, the coefficient of variance, defined as the ratio 
of the standard deviation to the mean, was calculated using 
the triplicate measurements that were made at each time point.
RESULTS
Patient Characteristics
Of 26 patients, 20 (77%) completed all exhaled breath 
measurements. The six remaining patients were unable to 
exhale long enough to allow for the acquisition of reliable 
measurements. Neither FEV1 nor diffusing capacity of the 
lung for carbon monoxide correlated significantly with abil-
ity to perform measurements. Patient, tumor, treatment, and 
toxicity characteristics are shown in Table 1 for the 20 evalu-
able patients. Five patients were diagnosed with RP (CTCAE 
grade ≥2) at a mean of 5.4 months after SABR. Three patients 
were treated for two synchronous tumors, two receiving treat-
ment for both tumors within the same course and the other in 
consecutive courses. The majority of patients received a dose 
of 50 Gy in four fractions.
Data Collection
Measurements of each gas were performed before 
and after each SABR fraction for 17 of the 20 evaluable 
FIGURE 1.  Sample NO and CO expiration profiles before and after SABR for patients that did and did not develop radiation 
pneumonitis (RP). Before SABR measurement shown in blue and after SABR measurement shown in red. Final concentrations 
were calculated as mean over the final 3 seconds of expiration, using American Thoracic Society/ European Respiratory Society 
recommendations for standardized measurement of exhaled NO. (A) NO expiration profile in patient who developed RP. (B) CO 
expiration profile in patient who developed RP. (C) NO expiration profile in patient who did not develop RP. (D) CO expiration 
profile in patient who did not develop RP.
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patients, including all patients who developed RP (see Table, 
Supplemental Digital Content 1, http://links.lww.com/JTO/
A582, which provides complete eNO, eCO, eN
2
O, eCO
2
, and 
dosimetric data for all evaluable patients). For the remaining 
three patients, only eCO, eN
2
O, and eCO
2
 data were obtained 
because of instrument error. The coefficient of variation for 
breath measurements performed in triplicate averaged 5.4% 
and never exceeded 8%.
Exhaled Breath Analysis
Sample eNO and eCO expiration profiles before and 
after SABR for patients that did and did not develop RP are 
shown in Fig. 1. Baseline eNO concentrations were gener-
ally elevated in patients destined to develop RP (p = 0.15; 
Fig. 2A; Table 2). Baseline eN
2
O and eCO
2
 did not associ-
ate with RP development (p = 0.88 and 0.47, respectively). 
As expected, baseline eCO was highly elevated in current 
smokers (p = 0.008; Fig. 2B). Of the six current smokers in 
the study cohort, none developed RP (p = 0.26; Fig. 2B).
Acute changes in exhaled breath component concentra-
tions are displayed in Table 2 and Figure 3. In general, eNO, 
eN
2
O, and eCO
2
 concentrations increased and eCO concen-
trations decreased immediately after single SABR fractions 
and returned to baseline levels by the next day of treatment. 
Average relative acute increases in eNO and decreases in 
eCO after single SABR fractions were significantly smaller 
in patients who developed RP compared with patients who 
did not (p = 0.022 and 0.015, respectively). Average abso-
lute acute changes in eNO and eCO were also smaller in 
patients that developed RP (p = 0.096 and 0.016, respec-
tively). Average acute changes in eN
2
O and eCO
2
 were not 
correlated with RP development (p = 0.30 and 0.39, respec-
tively). In an exploratory analysis, we found that four of five 
patients who developed RP had baseline eNO greater than 24 
ppb and acute decreases of eCO less than 5.5%, whereas only 
one of 12 patients who did not develop RP met these criteria 
(p = 0.0099).
Medications including bronchodilators, steroids, and 
leukotriene receptor antagonists can affect levels of eNO.15 
Seven patients had prescriptions for such medications at 
the time of enrollment and four reported using them within 
5 hours of at least one fraction. However, there were no sig-
nificant differences in mean pretreatment eNO measurements 
(p = 0.56) or acute eNO changes (p = 0.50) comparing these 
seven patients to the remaining 13 evaluable patients who did 
not use a medication that could affect eNO concentration.
Dosimetric Parameters
We also evaluated dosimetric parameters including 
total MLD, ipsilateral MLD, GTV, PTV, V
5
, V
10
, V
20
, V
30
, and 
V
40
 for correlation with RP development (Table 3). All dosi-
metric parameters were elevated in patients who developed 
RP; however, no parameter achieved statistical significance 
(p = 0.07–0.32). Dosimetric parameters were not significantly 
correlated with acute changes in eNO or eCO (data not shown).
DISCUSSION
In this prospective pilot study, we demonstrated the fea-
sibility of measuring the concentration of multiple exhaled 
gases immediately before and after delivery of SABR in 
patients with lung tumors. In addition, although our ability 
to detect significant associations was limited by the relatively 
small size of our cohort, we found evidence to suggest that 
baseline levels of eNO and acute changes in eNO and eCO 
represent potential early biomarkers for development of RP 
in this population. Our study is the first to measure multiple 
gases in exhaled breath after radiotherapy and the first to doc-
ument acute changes in exhaled breath composition imme-
diately after delivery of SABR. With appropriate validation, 
our findings suggest that multicomponent analysis of exhaled 
breath might be used to identify patients destined to develop 
clinically significant RP, thus potentially allowing early thera-
peutic intervention.
Several previous reports have examined whether 
changes in the concentration of eNO in exhaled breath after 
TABLE 1.  Patient, Tumor, Treatment, and Toxicity 
Characteristics for All Evaluable Patients
Parameter Total (%)
Patients 20
Age (y)
  Median 68
  Range 54–89
Sex
  M 14 (70)
  F 6 (30)
Total number of tumors treated 23
Patients with one tumor treated 17 (70)
Patients with two tumors treated 3 (30)
Location
  Right 14 (61)
  Left 9 (39)
  Central 6 (26)
  Peripheral 17 (74)
Primary lung 21 (91)
Metastatic 2 (9)
Histology (of primary lung tumors, N = 21)
  Adenocarcinoma 8 (35)
  Squamous 10 (43)
  NSCLC, NOS 3 (13)
Median GTV (cm3) 18.45
Median PTV (cm3) 55.36
Dose (Gy)
  Median 50
  Range 34–60
Number of fractions
  Median 4
  Range 1–5
Patients who developed RP 5 (25)
Patients who did not develop RP 15 (75)
NSCLC, non–small-cell lung cancer; NOS, not otherwise specified; GTV, gross 
tumor volume; PTV, planning target volume; RP, radiation pneumonitis.
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CFRT are associated with RP development.2,8–10 These stud-
ies found that elevated eNO levels at the end of multi-week 
courses (~6 weeks) of thoracic CFRT compared with pre-
treatment levels may predict RP development. In our SABR 
cohort, we did not observe increases in eNO levels when com-
paring baseline measurements before treatment to those on the 
final day of treatment (at most 4 days after the first fraction). 
This is consistent with our observation that cone beam CTs on 
the final day of treatment did not show signs of inflammatory 
infiltrates in the treated regions. We speculate that the differ-
ence in eNO responses after CFRT compared with SABR is 
because of the fact that not enough time had elapsed by the last 
SABR fraction for chronic elevation of eNO to occur, unlike 
after extended CFRT courses. It is possible that patients who 
will develop RP after SABR will also show elevated eNO at 
~6 weeks after treatment, and it will be interesting to explore 
this in future studies.
In contrast to these previous studies, we focused on 
patients treated with SABR. Given the larger doses of radio-
therapy delivered during SABR compared with CFRT, we 
examined immediate peri-fraction changes in exhaled breath 
composition. In addition, in contrast to prior studies in CFRT 
patients, we tested four different gases simultaneously. Use of 
multicomponent analysis allowed us to uncover a novel rela-
tionship between eCO and RP development. In an exploratory 
analysis, we also found that a bivariate predictor of baseline 
eNO greater than 24 ppb and acute decrease eCO less than 
5.5% was correlated with RP development. Future studies 
with greater patient numbers will be necessary to validate the 
thresholds identified here.
Increased levels of eNO and eCO have been exten-
sively studied as potential biomarkers in asthma and chronic 
obstructive pulmonary disease, which both involve airway 
inflammation.11 The exact cellular source of these gases and 
whether this source differs depending on the cause of lung 
inflammation remains unclear. NO in the lower respiratory 
tract is believed to be derived from airway, alveolar epithe-
lial, or inflammatory cells and is produced by nitric oxide syn-
thases.2,11 Therefore, higher levels of eNO at baseline likely 
reflect preexisting lung inflammation, which may explain why 
we observed these patients to have a higher risk for RP devel-
opment. The mechanism explaining the observation that a 
lower rise of eNO immediately after SABR is associated with 
development of RP is currently unclear and will be an area of 
future investigation. Because we measured changes in eNO 
a few minutes after irradiation, the source of this gas may be 
different than when it is measured several weeks into CFRT as 
done in previous studies.2,8–10 CO can be produced by the stress 
protein heme oxygenase and is a well known biomarker of 
FIGURE 2.  Dot plots of baseline exhaled NO and CO concentrations for patients that did and did not develop RP. Bars show 
average values. A, Baseline exhaled NO concentrations. (B) Baseline exhaled CO concentrations. Current nonsmokers shown as 
filled circles and current smokers shown as open circles.
TABLE 2.  Exhaled breath composition data for evaluable 
patients who did and did not develop RP. eNO, eCO, eN2O, 
and eCO2 measurements presented as mean ± standard error
Average Acute % Change
Gas
Developed RP 
(n = 5)
Did Not Develop RP 
(n = 15) p Value
eNO 4.1 ± 6.7 33.5 ± 9.3* 0.022
eCO −0.8 ± 1.5 −7.3 ± 1.8 0.015
eN
2
O 17.9 ± 5.6 28.2 ± 7.9 0.30
eCO
2
1.2 ± 1.0 2.5 ± 1.2 0.39
Baseline concentration
Gas
Developed RP 
(n = 5)
Did not develop RP 
(n = 15) p value
eNO 37.1 ± 7.9 (ppb) 21.8 ± 5.6 (ppb)* 0.15
eCO 1.82 ± 0.1 (ppm) 4.85 ± 1.1 (ppm) 0.017
eN
2
O 459 ± 38 (ppb) 450 ± 46 (ppb) 0.88
eCO
2
6.9 ± 0.3 (%) 6.3 ± 0.6 (%) 0.47
*NO data not available for 3 of 15 patients.
RP, radiation pneumonitis; ppb, parts per billion; ppm, parts per million.
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oxidative stress.11 Thus, smaller decreases (or even increases) 
in eCO concentrations immediately after SABR may reflect 
a decreased ability of patients to detoxify free radicals pro-
duced by SABR. Further studies will be required to clarify the 
mechanistic underpinnings of our findings.
Dosimetric parameters have previously been implicated 
as predictors of RP development.3,5–7 In our study, ipsilateral 
MLD, V
5
, V
10
, V
20
, V
30
, and V
40
 were not independently asso-
ciated with RP development. We believe this was most likely 
because of the relatively small sample size of our cohort. 
However, these findings also suggest that dosimetric param-
eters alone are imperfect predictors of RP development and 
that the addition of other predictive biomarkers would be of 
clinical utility.
Elevation of Krebs von den Lungen-6, surfactant pro-
tein D (SP-D), and lactate dehydrogenase in serum have also 
been reported to be potential RP biomarkers after SABR.3,17,18 
In addition, CT or x-ray imaging before and after SABR may 
help predict RP development.18 It therefore may be useful 
to assess breath biomarkers in combination with dosimetric 
parameters, blood biomarkers, and radiologic imaging to pre-
dict RP development in follow-up studies.
In previous studies, incidence of RP after lung SABR 
has been reported to range from 9% to 28% and in our study 
was 25%.3 The fact that our cohort falls in the upper end of 
this range is likely because of multiple reasons. For example, 
most of our tumors were the equivalent of T2 or greater, as evi-
denced by the median GTV of 18.45 cc (volume of a spherical 
tumor with 3 cm diameter is 14.1 cc) and a recent study found 
that T2 tumors were associated with significantly higher rates 
of RP (17.9%) than T1 tumors (4.4%).19 In addition, our pilot 
cohort was relatively small and therefore may have included 
an additional RP case by chance, leading to a rate of RP that 
was higher than anticipated.
No current smokers enrolled in our study developed 
RP, which is consistent with several studies that found lower 
rates of RP in active smokers. A recent meta-analysis of RP 
risk factors after CFRT concluded that ongoing smoking pro-
tected against RP.20 This observation could be because of an 
increased risk for chronic coughing in smokers, which could 
mask symptoms of mild RP. However, bronchoalveolar lavage 
fluid has been shown to contain reduced levels of mast cells 
and lymphocytes in smokers compared with nonsmokers after 
irradiation. These observations are consistent with active 
smoking leading to a reduction of the inflammatory response 
normally induced by irradiation.21
Our study had several limitations. First, because this was 
a pilot study our cohort was relatively small and we observed 
a limited number of RP cases. Our study was powered for fea-
sibility and therefore the inferential comparisons should be 
considered to be exploratory. Second, although the majority of 
patients received 50 Gy in four fractions, there was some vari-
ability in total dose and fractionation within the study cohort. 
FIGURE 3.  Dot plots of average acute percent changes in exhaled NO and CO after SABR for patients that did and did not 
develop RP. Bars show average values. The independent samples t test was used to assess significance. A, average acute change 
in exhaled NO after SABR. (B) Average acute change in exhaled CO after SABR.
TABLE 3.  Dosimetric Parameters for Patients Who Did and 
Did Not Develop RP
Parameter
Developed RP 
(n = 5)
Did Not Develop RP 
(n = 15) p-value
V
5
33.7 ± 8.2 18.4 ± 2.7 0.14
V
10
19.6 ± 4.0 10.6 ± 1.7 0.09
V
20
9.6 ± 2.1 4.7 ± 0.7 0.07
V
30
5.2 ± 1.3 2.5 ± 0.4 0.11
V
40
3.0 ± 0.8 1.5 ± 0.3 0.14
Ipsilateral lung MLD (Gy) 9.2 ± 1.8 6.0 ± 0.7 0.16
Total lung MLD (Gy) 5.7 ± 1.0 3.9 ± 0.5 0.17
GTV (mL) 33.0 ± 14.2 16.7 ± 3.6 0.32
PTV (mL) 86.5 ± 21.6 48.6 ± 7.4 0.16
Each DVH parameter was dichotomized based on the median. 
Data presented as mean ± standard error.
V5, percent of total lung receiving ≥5 Gy; V10, percent of total lung receiving ≥10 
Gy; V20, percent of total lung receiving ≥20 Gy; V30, percent of total lung receiving 
≥30 Gy; V40, percent of total lung receiving ≥40 Gy; MLD, mean lung dose; GTV, gross 
tumor volume; PTV, planning treatment volume; RP, radiation pneumonitis.
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Third, measurement of eNO is complicated by the fact that a 
variety of factors ranging from respiratory tract inflammation 
because of viral infection to bronchodilator/inhaled steroid 
use to recent smoking can affect levels of eNO.2 While not as 
well characterized, similar phenomena may also affect con-
centrations of the other gases we measured. We attempted to 
mitigate these confounders by careful patient history taking 
before each measurement.
It will be important for future studies to enroll larger 
and more homogeneous cohorts. For example, patients 
who receive radiotherapy to more than one site are likely 
inherently at increased risk for developing RP as they are 
more likely to receive larger doses to the lung. Therefore, it 
would be reasonable to exclude these patients from future 
studies or to analyze them as an independent subgroup. 
Furthermore, we believe periodic follow-up measure-
ments (i.e., measurements taken at regular intervals after 
administration of SABR) would be a valuable addition to 
future studies, as they could help to elucidate the currently 
unknown long-term time course of changes in exhaled 
breath composition after SABR. Future studies should also 
be designed to conclusively demonstrate the robustness 
and reproducibility of our findings. Although we found 
the concentrations of each gas to be measured in a very 
reproducible fashion at each time point (average coefficient 
of variation = 5.4%), it will be important to reproduce the 
cutoffs for baseline eNO and acute changes in eCO that 
we found to be associated with development of RP. Finally, 
predicated on the availability of a validated predictor of 
RP risk, it would be interesting to test prophylactic use of 
anti-inflammatory therapies in high-risk patients. A num-
ber of drugs have previously been suggested to potentially 
decrease development of RP, including inhaled or systemic 
steroids, cyclooxygenase-2 inhibitors, and angiotensin-
converting enzyme inhibitors, and one or more of these 
would be worth exploring in such a study.22–24
In conclusion, in this prospective pilot study, we 
found that multicomponent exhaled breath analysis is fea-
sible in SABR patients. In addition, elevated baseline eNO 
concentrations in combination with small acute changes in 
eCO strongly correlated with RP development. Our find-
ings suggest that evaluation of eNO and eCO concentra-
tions before and immediately after SABR may represent a 
potential approach for identifying individuals at highest risk 
for developing RP. If confirmed, this noninvasive biomarker 
could be used as the basis for prospective studies examining 
early intervention with anti-inflammatory therapies in high-
risk patients.
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